SCHEMBL23248802

SCHEMBL23248802

Cc1c(N)cccc1-c1cccc(B2OC(C)(C)C(C)(C)O2)c1Cl

nearest known ligand 0.39

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.39
JAK2 O60674 3/20 0.36
BTK Q06187 3/20 0.36
CYP3A4 P08684 1/20 0.36
TSHR P16473 1/20 0.36
PIK3CA P42336 1/20 0.36
HPGD P15428 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
LPL P06858 2/20 0.31
LIPG Q9Y5X9 2/20 0.31
CD44 P16070 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23199759 0.90 JAK2 (0.33) ALDH1A1JAK2BTKLPLLIPG
SCHEMBL24109664 0.88 CYP3A4 (0.41) ALDH1A1JAK2BTKCYP3A4TSHR
SCHEMBL20540203 0.86 LPL (0.39) JAK2BTKLPLLIPG
SCHEMBL1494643 0.83 LPL (0.37) ALDH1A1JAK2BTKCYP3A4TSHR
SCHEMBL29503402 0.81 CYP3A4 (0.46) ALDH1A1JAK2BTKCYP3A4TSHR
SCHEMBL106726 0.81 CYP3A4 (0.46) ALDH1A1JAK2BTKCYP3A4TSHR
SCHEMBL23202718 0.81 KDM1A (0.31) ALDH1A1
SCHEMBL29993417 0.79 JAK2 (0.39) ALDH1A1JAK2BTKHPGDSMN1; SMN2
SCHEMBL20540300 0.78 JAK2 (0.41) JAK2BTKLPLLIPG
SCHEMBL29724522 0.78 JAK2 (0.41) JAK2BTKLPLLIPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4045036-B1 HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES CHEMOCENTRYX INC (US) 2026-03-04 EP disclosed
EP-4045037-B1 HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES CHEMOCENTRYX INC (US) 2026-01-28 EP disclosed
US-12497383-B2 Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases CHEMOCENTRYX, INC. (US) 2025-12-16 US disclosed
US-20250346598-A1 HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES CHEMOCENTRYX, INC. (US) 2025-11-13 US disclosed
US-12371433-B2 Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases AMGEN INC. (US) 2025-07-29 US disclosed
US-20240132495-A1 HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES CHEMOCENTRYX, INC. (US) 2024-04-25 US disclosed
US-11866429-B2 Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases CHEMOCENTRYX, INC. (US) 2024-01-09 US disclosed
US-20230322731-A1 HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES CHEMOCENTRYX, INC. 2023-10-12 US disclosed
US-11713307-B2 Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases CHEMOCENTRYX, INC. (US) 2023-08-01 US disclosed
EP-4045036-A1 HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES ChemoCentryx, Inc. (US) 2022-08-24 EP disclosed
EP-4045037-A1 HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES ChemoCentryx, Inc. (US) 2022-08-24 EP disclosed
CN-114585359-A Heteroaryl benzidines for the treatment of PD-L1 diseases 凯莫森特里克斯股份有限公司 2022-06-03 CN disclosed
US-20210130347-A1 HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES CHEMOCENTRYX, INC. 2021-05-06 US disclosed
US-20210130325-A1 HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES CHEMOCENTRYX, INC. 2021-05-06 US disclosed
WO-2021076688-A1 HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES CHEMOCENTRYX, INC. (US) 2021-04-22 WO disclosed
WO-2021076691-A1 HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES CHEMOCENTRYX, INC. (US) 2021-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12497383-B2 Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases CD274, PDCD1LG2, PDCD1 ALDH1A1 463/4885JAK2 165/4885BTK 1415/4885
US-20230322731-A1 HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES CD274, PDCD1LG2, PDCD1 ALDH1A1 463/4885JAK2 165/4885BTK 1415/4885
US-12371433-B2 Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases CD274, PDCD1LG2, PDCD1 ALDH1A1 332/4885JAK2 110/4885BTK 1064/4885
US-11713307-B2 Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases CD274, PDCD1LG2, PDCD1 ALDH1A1 463/4885JAK2 165/4885BTK 1415/4885
US-20250346598-A1 HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES CD274, PDCD1LG2, PDCD1 ALDH1A1 332/4885JAK2 110/4885BTK 1064/4885
US-20210130347-A1 HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES CD274, PDCD1LG2, PDCD1 ALDH1A1 332/4885JAK2 110/4885BTK 1064/4885
US-11866429-B2 Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases CD274, PDCD1LG2, PDCD1 ALDH1A1 332/4885JAK2 110/4885BTK 1064/4885
US-20210130325-A1 HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES CD274, PDCD1LG2, PDCD1 ALDH1A1 463/4885JAK2 165/4885BTK 1415/4885
US-20240132495-A1 HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES CD274, PDCD1LG2, PDCD1 ALDH1A1 378/4885JAK2 99/4885BTK 1039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.